C3i was proud to participate in Advanced Therapies Week, which took place in Dallas from January 20 to 23, 2025.
As a key event in the biotech industry, ATW 2025 gathered 2,500 attendees, 100 investors, 600 biotech companies, and 180 exhibitors at the Kay Bailey Hutchinson Convention Center. With six content tracks and 250 expert speakers, the event fostered innovation, regulatory discussions, and strategic collaborations to advance the future of cell and gene therapies.
This conference, organized by Phacilitate, provided a valuable opportunity to connect with industry leaders, share knowledge, and stay at the forefront of what we do best: bringing life-saving cell therapies from the laboratory to the clinic.
For the first time in Canada, blood stem cells were genetically modified using CRISPR-Cas9 technology and subsequently injected into patients as part of a North American clinical trial targeting acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). Every graft used in this landmark study was produced in Montreal, at Hôpital Maisonneuve-Rosemont, through the biomanufacturing expertise […]
Montreal CDMO expands beyond cell therapy manufacturing with companion diagnostics, therapeutic monitoring, and integrated patient support programs. What if every patient received a therapy tailored to their unique biology? That question, aligned with the aspirational promise of precision medicine, is now at the heart of what C3i does. The Montreal-based contract development and manufacturing organization […]
From April 7 to 9, 2026, C3i took part in the 4th Pan-Canadian Strategic Forum on Cell and Gene Therapies, organized by CellCAN at the Sheraton Laval & Convention Center. The event brought together key players in the sector, including scientists, innovators, and partners from the cell and gene therapy biomanufacturing ecosystem, around a […]
